Nav: Home

Can DXA be used to predict fracture risk in people with diabetes?

December 01, 2016

Increased risk of fracture has been shown to be one of the complications arising from longstanding diabetes. With the worldwide increase in Type 2 Diabetes (T2D), in part due to aging populations, there is also increasing concern about how to identify and manage patients with diabetes who are at high risk of osteoporotic fracture.

Osteoporosis is usually diagnosed from bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA). The authors reviewed data on skeletal parameters and techniques readily available from DXA scanning, and considered their utility in routine clinical practice for predicting fracture risk. DXA measures BMD as well these other applications and measurements: trabecular bone score (TBS), skeletal geometry and DXA-based finite-element analysis, vertebral fracture assessment (VFA), and body composition.

They also looked at fracture prediction tools, and specifically at the widely used Fracture Risk Assessment Tool (FRAX®) which is incorporated into modern DXA scanners. FRAX underestimates fracture risk in individuals with T2D - with factors contributing to this underestimation including the higher BMD observed in T2D, the greater risk for falls, and alterations in material strength. Nevertheless, several methods have been proposed to improve the performance FRAX in T2D.

The review summarizes the evidence for the effect of various DXA-derived skeletal parameters in T1D and T2D. In regard to whether they can be used to account for the excess fracture risk, the review concludes:
  • In Type 1 Diabetes (T1D), BMD and FRAX (when secondary osteoporosis is included without BMD) only partially account for the excess risk of fracture in T1D. It is uncertain whether bone geometry, TBS, VFA or body composition account for excess fracture risk in T1D.

  • In Type 2 Diabetes (T2D), BMD and FRAX can be used to stratify fracture risk, but do not account for the increased risk of fracture. However, several adjustments to the FRAX score can be made as proxies for T2D to inform the use of FRAX by primary care practitioners. Examples include the rheumatoid arthritis input (as a proxy for T2D), lumbar spine TBS (to adjust FRAX probability) or an altered hip T-score (lowered by 0.5 units). TBS is associated with increased fracture risk, and may partially account for excess risk of fracture. It remains uncertain whether bone geometry, VFA, or body composition differ between those with or without T2D, or whether they are associated with increased or excess fracture risk.

Lead author Professor William D. Leslie of the Department of Medicine, University of Manitoba, Canada stated:

"Diabetes is associated with increased fracture risk that is only partially reflected by the BMD reductions see in in T1D, and is underestimated in T2D where BMD is increased. While BMD from DXA still stratifies fracture risk in those with diabetes, additional measures that can be obtained from DXA help to identify high-risk patients. Incorporating this additional information into risk prediction models may help to avoid systematically underestimating the risk of osteoporosis-related fractures in people with diabetes."
Reference: Schacter G I, Leslie W D. DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk? Calcif Tissue Int. DOI 10.1007/s00223-016-0191-x

Calcified Tissue International & Musculoskeletal Research

Calcified Tissue International & Musculoskeletal Research is a peer-reviewed journal which publishes original preclinical, translational and clinical research, and reviews concerning the structure and function of bone, and other musculoskeletal tissues in living organisms, as well as clinical studies of musculoskeletal disease. It includes studies of cell biology, molecular biology, intracellular signalling, and physiology, as well as research into the hormones, cytokines and other mediators that influence the musculoskeletal system. The journal also publishes clinical studies of relevance to bone disease, mineral metabolism, muscle function, and musculoskeletal interactions.

Editors in Chief: Stuart Ralston and René Rizzoli; Musculoskeletal Research Section Editor: Roger Fielding.

> Become an IOF Professional member to freely access IOF scientific journals via the IOF website:

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 234 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. /

International Osteoporosis Foundation

Related Diabetes Articles:

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
More Diabetes News and Diabetes Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...